JP2018532742A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532742A5 JP2018532742A5 JP2018520486A JP2018520486A JP2018532742A5 JP 2018532742 A5 JP2018532742 A5 JP 2018532742A5 JP 2018520486 A JP2018520486 A JP 2018520486A JP 2018520486 A JP2018520486 A JP 2018520486A JP 2018532742 A5 JP2018532742 A5 JP 2018532742A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- rna
- fold
- protamine
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022015705A JP2022062175A (ja) | 2015-10-21 | 2022-02-03 | 免疫応答を誘導するための方法および手段 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2015/074389 | 2015-10-21 | ||
| PCT/EP2015/074389 WO2017067593A1 (en) | 2015-10-21 | 2015-10-21 | Methods and means for inducing an immune response |
| PCT/EP2016/075156 WO2017068016A1 (en) | 2015-10-21 | 2016-10-20 | Methods and means for inducing an immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022015705A Division JP2022062175A (ja) | 2015-10-21 | 2022-02-03 | 免疫応答を誘導するための方法および手段 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532742A JP2018532742A (ja) | 2018-11-08 |
| JP2018532742A5 true JP2018532742A5 (enExample) | 2019-08-15 |
| JP7021083B2 JP7021083B2 (ja) | 2022-02-16 |
Family
ID=54347522
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520486A Expired - Fee Related JP7021083B2 (ja) | 2015-10-21 | 2016-10-20 | 免疫応答を誘導するための方法および手段 |
| JP2022015705A Pending JP2022062175A (ja) | 2015-10-21 | 2022-02-03 | 免疫応答を誘導するための方法および手段 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022015705A Pending JP2022062175A (ja) | 2015-10-21 | 2022-02-03 | 免疫応答を誘導するための方法および手段 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20180318436A1 (enExample) |
| EP (1) | EP3365024A1 (enExample) |
| JP (2) | JP7021083B2 (enExample) |
| AU (1) | AU2016341181A1 (enExample) |
| CA (1) | CA2996467A1 (enExample) |
| WO (2) | WO2017067593A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017067592A1 (en) | 2015-10-21 | 2017-04-27 | Biontech Ag | Cytotoxic immunostimulating particles and uses thereof |
| SG11202101732WA (en) | 2018-10-01 | 2021-03-30 | Univ Mainz Johannes Gutenberg | Rna particles comprising polysarcosine |
| WO2021001023A1 (en) * | 2019-07-02 | 2021-01-07 | Biontech Rna Pharmaceuticals Gmbh | Rna formulations suitable for therapy |
| JP2022545786A (ja) * | 2019-09-01 | 2022-10-31 | アカデミア シニカ | ナノコンポジット粒子及びその使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2200639B1 (en) * | 2007-09-24 | 2016-03-30 | Government of the USA, as Represented by the Secretary, Department of Health and Human Services | Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use |
| WO2009046739A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| US20110123637A1 (en) | 2008-05-26 | 2011-05-26 | Universitat Zurich | Protamine/rna nanoparticles for immunostimulation |
-
2015
- 2015-10-21 WO PCT/EP2015/074389 patent/WO2017067593A1/en not_active Ceased
-
2016
- 2016-10-20 JP JP2018520486A patent/JP7021083B2/ja not_active Expired - Fee Related
- 2016-10-20 WO PCT/EP2016/075156 patent/WO2017068016A1/en not_active Ceased
- 2016-10-20 EP EP16784491.9A patent/EP3365024A1/en not_active Withdrawn
- 2016-10-20 AU AU2016341181A patent/AU2016341181A1/en not_active Abandoned
- 2016-10-20 US US15/763,601 patent/US20180318436A1/en not_active Abandoned
- 2016-10-20 CA CA2996467A patent/CA2996467A1/en active Pending
-
2022
- 2022-02-03 JP JP2022015705A patent/JP2022062175A/ja active Pending
- 2022-07-18 US US17/867,128 patent/US20220347308A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases | |
| Apostolico et al. | Adjuvants: classification, modus operandi, and licensing | |
| Yong et al. | RIG-I-like receptors as novel targets for pan-antivirals and vaccine adjuvants against emerging and re-emerging viral infections | |
| Chi et al. | Anti-tumor activity of toll-like receptor 7 agonists | |
| Liu et al. | Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments | |
| TWI696630B (zh) | 含有具有免疫賦活活性之寡核苷酸之複合體及其用途 | |
| JP2018532742A5 (enExample) | ||
| Jiang et al. | Type I IFN signaling facilitates the development of IL‐10‐producing effector CD8+ T cells during murine influenza virus infection | |
| JP2019501661A5 (enExample) | ||
| JP2007211026A5 (enExample) | ||
| JP2012136541A5 (enExample) | ||
| Lu et al. | The incorporation of cationic property and immunopotentiator in poly (lactic acid) microparticles promoted the immune response against chronic hepatitis B | |
| JP2016512248A5 (enExample) | ||
| Fu et al. | Effects of different CpG oligodeoxynucleotides with inactivated avian H5N1 influenza virus on mucosal immunity of chickens | |
| Jiang et al. | Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice | |
| CN113891939A (zh) | 核酸、药物组合物与缀合物及制备方法和用途 | |
| CN109963944A (zh) | 体外敲除T细胞中靶基因的方法以及该方法中使用的crRNA | |
| CN105264074A (zh) | 共价闭合的非编码免疫调节性dna构建体 | |
| Iyer et al. | Bioengineering strategies for developing vaccines against respiratory viral diseases | |
| Baydemir et al. | Trained immunity-inducing vaccines: Harnessing innate memory for vaccine design and delivery | |
| Chai et al. | Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis | |
| Azizi et al. | Self-amplifying RNAs generated with the modified nucleotides 5-methylcytidine and 5-methyluridine mediate strong expression and immunogenicity in vivo | |
| WO2016152767A1 (ja) | 免疫賦活活性を有するＣｐＧスペーサーオリゴヌクレオチド含有複合体及びその用途 | |
| Beagan et al. | Fucoidans from Laminaria hyperborea demonstrate bactericidal activity against diverse bacteria | |
| Nantachit et al. | EDIII‐DENV3 nanospheres drive immature dendritic cells into a mature phenotype in an in vitro model |